Tumour-penetrating microparticles - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Tumour-penetrating microparticles


Pharmaceutical Technology Europe
Volume 22, Issue 1

Tumour-penetrating microparticles (TPM), drug delivery vehicles that have been designed to specifically target and infiltrate peritoneal tumours, are more efficacious than standard chemotherapy, according to our preliminary research data.1

The peritoneal cavity contains organs, such as the pancreas, liver, colon and ovary, that are responsible for a large portion of cancer deaths. Pancreatic cancer cells, for example, are surrounded by a specialized network of cells and proteins that present the biggest hurdle to chemotherapeutic delivery, and hence treatment success. Our goal was to develop a drug delivery system that would effectively target and penetrate these barriers and deliver drug directly to the cancer cells.

How does it work?

Specifically, TPM is paclitaxelloaded poly(lactide-co-glycolide) microparticles with several features that improve the targeting of tumours in the intraperitoneal and retroperitoneal cavity, including:
  • Size: The average size of TPM (5 Ám) is optimized to limit clearance from the peritoneal cavity, and to enable wide distribution in the cavity and penetration into tumours.
  • Polymer properties: TPM selectively adheres to the tumour surface.
  • Multifunctional delivery system: TPM comprises two components of paclitaxel-loaded particles. One component provides rapid drug release to induce tumour priming (a technology that uses paclitaxel to transiently expand the interstitial space, and is tumour-selective because of the greater susceptibility of tumour cells to drug-induced apoptosis compared with normal cells). The tumour priming feature of TPM enables the drug/particles to penetrate the inner layers of tumours. The second component of the delivery system releases the remainder of the dose slowly over the course of several weeks. This twotiered drug attack is unique in pancreatic cancer treatment.

The collective properties of TPM result in tumour-selective delivery, reduced drug exposure in normal tissues, and control of rapidly and slowly growing tumours.

According to our research, one dose of TPM, administered intraperitoneally, is as effective as multiple injections of chemotherapy; it is present in the peritoneal lavage for at least 1 week2 and for at least 4 weeks in peritoneal tumours.3 The delivery system is specifically tailored to the unique anatomical properties of the abdominal cavity, targets the tumours and releases the drug contents at pharmacodynamically optimized rates. This fractionated dose presentation reduces the local toxicity whilst eliminating the need for repeated catheterization.

In practice

Multiple clinical trials have shown that instilling a drug solution directly into the peritoneal cavity can effectively treat tumours originating from organs in the peritoneal cavity, such as ovarian cancer. This mode of administration, however, poses two limitations that have prevented its widespread use, despite its demonstrated efficacy: local toxicity and inability of the drug to penetrate bulky tumours. TPM is designed to overcome these limitations, and represents a delivery platform that can be used to deliver small molecule therapeutics, biologics, gene vectors and imaging agents directly to peritoneal tumours.

We have been working on TPM for more than 10 years now and we anticipate approval from the FDA to take our candidate into clinical trials this year.

References

1. J.L-S. Au, et al., "Tumor penetrating microparticles for intraperitoneal treatment of pancreatic cancer," presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition (Los Angeles, CA, USA, 8–12 November 2009).

2. M. Tsai, et al., Pharm. Res., 24(9), 1691–1701 (2007).

3. Z. Lu et al., J. Pharmacol. Exp. Ther., 327(3), 673–682 (2008).

Professor Au's research was presented at the 2009 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, 8–12 November 2009, Los Angeles, USA.

Professor Au is co-founder of Optimum Therapeutics LLC, the company hoping to take TPM to clinical trials.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
29%
Breakthrough designations
10%
Protecting the supply chain
43%
Expedited reviews of drug submissions
10%
More stakeholder involvement
10%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology Europe,
Click here